“Maintenance of Clinical Response With Continued Risankizumab Treatment for Moderate-to-Severe Psoriasis Through 304 Weeks: Interim Analysis of the LIMMitless Open-Label Extension Study”. SKIN The Journal of Cutaneous Medicine, vol. 7, no. 6, Nov. 2023, p. s258, https://doi.org/10.25251/skin.7.supp.258.